- Home
- NXTC vs FSEA Comparison
NXTC vs FSEA Comparison
Compare NXTC & FSEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- FSEA
- Stock Information
- Founded
- NXTC 2015
- FSEA 1890
- Country
- NXTC United States
- FSEA United States
- Employees
- NXTC N/A
- FSEA N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- FSEA Savings Institutions
- Sector
- NXTC Health Care
- FSEA Finance
- Exchange
- NXTC Nasdaq
- FSEA Nasdaq
- Market Cap
- NXTC 40.3M
- FSEA 44.0M
- IPO Year
- NXTC 2019
- FSEA N/A
- Fundamental
- Price
- NXTC $1.31
- FSEA $9.14
- Analyst Decision
- NXTC Strong Buy
- FSEA
- Analyst Count
- NXTC 2
- FSEA 0
- Target Price
- NXTC $4.00
- FSEA N/A
- AVG Volume (30 Days)
- NXTC 44.0K
- FSEA 6.2K
- Earning Date
- NXTC 11-07-2024
- FSEA 11-08-2024
- Dividend Yield
- NXTC N/A
- FSEA N/A
- EPS Growth
- NXTC N/A
- FSEA N/A
- EPS
- NXTC N/A
- FSEA N/A
- Revenue
- NXTC N/A
- FSEA $11,390,000.00
- Revenue This Year
- NXTC N/A
- FSEA N/A
- Revenue Next Year
- NXTC N/A
- FSEA N/A
- P/E Ratio
- NXTC N/A
- FSEA N/A
- Revenue Growth
- NXTC N/A
- FSEA N/A
- 52 Week Low
- NXTC $1.03
- FSEA $6.25
- 52 Week High
- NXTC $2.57
- FSEA $9.49
- Technical
- Relative Strength Index (RSI)
- NXTC 45.61
- FSEA 50.72
- Support Level
- NXTC $1.30
- FSEA $9.00
- Resistance Level
- NXTC $1.60
- FSEA $9.35
- Average True Range (ATR)
- NXTC 0.08
- FSEA 0.12
- MACD
- NXTC 0.00
- FSEA 0.00
- Stochastic Oscillator
- NXTC 12.12
- FSEA 40.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities and bank-owned life insurance.